



an Open Access Journal by MDPI

Half-Life Extension of Therapeutic Antibodies

Guest Editor:

Dr. Tilman Schlothauer

Roche Innovation Center, Large
Molecule Research, Roche
Pharma Research and Early
Development (pRED), Munich,
Germany

Deadline for manuscript
submissions:

closed (10 April 2022)

Message from the Guest Editor

Dear Colleagues,

The number of therapeutic antibodies in clinical development has been continuously increasing over the last several decades. Monoclonal therapeutic antibodies are established as classical immunoglobulin G (IgG)-like scaffolds such as more complex formats with novel functions and differentiated mechanisms of action. IgG1, the most abundant isotype, has the longest half-life amongst the immunoglobulins due to the pH-dependent active FcRn-mediated recycling mechanism. This Special Issue of *Antibodies* aims to collect original manuscripts and reviews covering the attempts made so far to engineer IgG-based formats for significant half-life extensions, including the research activity that was needed to understand this mechanism in more detail to repair unexpected fast clearance of complex novel IgG-based formats.

Dr. Tilman Schlothauer

Guest Editor



mdpi.com/si/95276

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: CiteScore - Q2 (*Drug Discovery*)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
X@Antibodies_MDPI